← Leaderboards
Pinar Karaca-Mandic
Rand Corporation
$4,055,014
Attributed
$4,055,014
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $633.7K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
AHRQ$2,637,690 · 3
NIH$1,417,324 · 3
By mechanism
R01$2,537,690 · 2
R56$633,737 · 1
K01$616,854 · 1
R03$266,733 · 2
Top collaborators
No co-investigators on record.
Most similar at Rand Corporation
Same institution · by research overlap
- Darius N. Lakdawalla$3,586,901
- Nancy Nicosia$7,327,017
- Rebecca Kilburn$938,069
- Beau Griffin Kilmer$1,500,784
- Kandice Ann Kapinos$461,356
Others in their field
Top investigators on “Interest”
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Antonio J Busalacchi · University Of Maryland, College Park$243,972,016
- Everette D Joseph · Howard University$243,972,016
- Eric J Barron · Pennsylvania State Univ University Park$243,972,016
- David Heimbrook · Leidos Biomedical Research, Inc.$231,553,599
- Clare E Reimers · Gordon Research Conferences$206,081,841
Research focus
InterestLiteratureVariantAdoptionServicesSurveysTrainingInnovationMedicalMarketingPhysician&AposPhysiciansAdoptedS RoleFundingHospitalsCharacteristicsHealth Care CostsAffectDiffuseDiffusionIncentivesMedicareMedical Technology
Grant awards (16)
Rapid learning during a public health emergency: COVID-19 related medication treatment patterns in Medicare$388,813
R01 · FY2025 · HS · contact PI
Rapid learning during a public health emergency: COVID-19 related medication treatment patterns in Medicare$387,463
R01 · FY2024 · HS · contact PI
Rapid learning during a public health emergency: COVID-19 related medication treatment patterns in Medicare$399,663
R01 · FY2023 · HS · contact PI
Medical reversals: De-implementing ineffective and unsafe treatments$330,164
R01 · FY2020 · HS · contact PI
Medical reversals: De-implementing ineffective and unsafe treatments$335,000
R01 · FY2019 · HS · contact PI
Medical reversals: De-implementing ineffective and unsafe treatments$298,000
R01 · FY2018 · HS · contact PI
Medical reversals: De-implementing ineffective and unsafe treatments$398,587
R01 · FY2017 · HS · contact PI
Diffusion of Clinical Evidence into Practice: Physician Networks, Delivery Organizations, and Markets$633,737
R56 · FY2016 · HL · contact PI
Physician Level Analysis of Medical Technology Diffusion: Coronary Stents Study$123,924
K01 · FY2014 · AG · contact PI
Physician Level Analysis of Medical Technology Diffusion: Coronary Stents Study$123,924
K01 · FY2013 · AG · contact PI
Physician Level Analysis of Medical Technology Diffusion: Coronary Stents Study$123,996
K01 · FY2012 · AG · contact PI
Physician Level Analysis of Medical Technology Diffusion: Coronary Stents Study$123,996
K01 · FY2011 · AG · contact PI
Physician Level Analysis of Medical Technology Diffusion: A Study of Coronary Ste$121,014
K01 · FY2010 · AG · contact PI
The Role of Agents and Brokers in the Market for Health Insurance - Do They Help$100,000
R03 · FY2009 · HS · contact PI
Analysis of Graduate Driver Licensing: Lower Risk Exposure or Better Driving?$73,311
R03 · FY2007 · HD · contact PI
Graduate Driver Licensing: Lower Exposure/Better Driving$93,422
R03 · FY2006 · HD · contact PI